Key Takeaways:
Japan's MHLW approved Takeda's ORZEYFUL (oveporexton) for narcolepsy type 1 in adults, the first orexin agonist cleared in the country.
"Our discovery of the first orexin agonist is a successful representation of Japan-originated science that will directly impact people around the world living with narcolepsy type 1," Julie Kim, president and chief executive officer of Takeda, said.
ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the underlying disease rather than individual symptoms. Oveporexton selectively stimulates OX2R to restore orexin signaling, promoting wakefulness and reducing abnormal rapid eye movement (REM) sleep phenomena, including cataplexy. The discovery of this new drug class originated in Takeda's laboratories in Japan. The approval was supported by the global phase 3 FirstLight and RadiantLight trials, which demonstrated statistically significant improvements across excessive daytime sleepiness, cataplexy, and health-related quality of life compared with placebo.
The most common adverse effects were insomnia, which developed in up to 60 percent of oveporexton-treated patients in pooled phase 3 studies versus 1 percent on placebo, along with urinary urgency, urinary frequency, and excessive salivation. Asymptomatic creatine phosphokinase elevations greater than five times the upper limit of normal were also observed more often with oveporexton than placebo. ORZEYFUL is contraindicated with strong CYP3A inhibitors.
The Japan approval follows the US FDA's Aug. 5 clearance of ORZEYFUL and a prior approval in China, giving Takeda a first-mover position in the orexin agonist class across three major markets. Takeda is proceeding with launch preparations and expects to make ORZEYFUL available in Japan as quickly as possible. The company is also developing additional orexin agonists, including TAK-360 for NT1, narcolepsy type 2, and idiopathic hypersomnia, and TAK-495.
Narcolepsy type 1 is a rare, chronic neurological disease caused by the loss of orexin-producing neurons, affecting an estimated 120,000 people in the US alone. The condition produces a persistent 24-hour symptom burden that includes excessive daytime sleepiness, cataplexy, cognitive symptoms, and disrupted nighttime sleep, with effects extending into work, education, and social functioning.
"As the first and only approved orexin therapy to treat the broad spectrum of the disease, Orzeyful can enable a different kind of conversation in the doctor's office about treatment options," Emmanuel Mignot, MD, PhD, principal US investigator for the Orzeyful phase 3 program, said.
The approval gives Takeda a first-mover position in a new drug class with potential multi-billion-dollar revenue opportunity. Investors will watch the pace of the Japan launch and the DEA's controlled-substance scheduling decision in the US, expected within 90 days of the FDA approval, as the next events to watch. Takeda said the approval is not expected to materially affect its consolidated financial forecast for the fiscal year ending March 31, 2027.
This article is for informational purposes only and does not constitute investment advice.
